$Codexis (CDXS.US)$
REDWOOD CITY, Calif., Oct. 10, 2024 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ:CDXS), a leading provider of enzymatic solutions for efficient and scalable therapeutics manufacturing, today announced that it will report its financial results for the third quarter of 2024 on Thursday, October 31, 2024, following the close of market. Codexis management will host a conference call and webcast at 4:30 pm E...

$Codexis (CDXS.US)$
Codexis is on the verge of launching an innovative platform for the efficient production of siRNA therapeutics, known as the ECO Synthesis™ Manufacturing Platform. The company has presented promising data that suggests this platform could overcome the scalability and cost limitations of traditional phosphoramidite chemistry used in oligonucleotide synthesis.
investing.com/n...

$Codexis (CDXS.US)$
Codexis Increases Cash Reserves and Enhances Management Team to Fuel Growth of Company | CDXS Stock News

$Codexis (CDXS.US)$
Codexis Licenses Genomics Life Science Enzyme Portfolio to Alphazyme LLC, part of Maravai LifeSciences
Codexis, Inc. (NASDAQ: CDXS) has entered into a non-exclusive commercial and manufacturing license agreement with Alphazyme , part of Maravai LifeSciences, for multiple enzymes in Codexis' life science enzyme portfolio. The agreement includes licenses for HiFi DNA Polymerase, HiTemp Reverse Transcriptase, HiRev Isothermal Polymerase and other enzymes for genomics and dia...

$Codexis (CDXS.US)$
Wall Street SWOT: Codexis stock pivots to RNAi, analysts see enzyme potential By Investing.com

$Codexis (CDXS.US)$
Codexis(CDXS.US) 10% Shareholder Buys US$3.31 Million in Common Stock
$Codexis(CDXS.US)$ 10% Shareholder Opale
https://www.moomoo.com/t/news/post/43819593/VZfqUR2zVf

$Codexis (CDXS.US)$
Opaleye Management Inc., a significant shareholder in Codexis , Inc. (NASDAQ:CDXS), has recently increased its stake in the company through the purchase of additional shares. On September 18, 2024, Opaleye Management executed two separate transactions, acquiring a total of 61,000 shares of Codexis common stock at an average price of $3.1638 per share, amounting to a total investment of approximately $193,000.
The bulk of the purchase consisted of 55,000 shar...

$Codexis (CDXS.US)$
NEWS
Codexis Presents Groundbreaking Enzymatic Synthesis Data at TIDES USA Annual Meeting
On May 14, 2024, Codexis (NASDAQ: CDXS) announced a significant milestone in enzymatic synthesis at the TIDES USA annual meeting. The company successfully synthesized a full-length oligonucleotide via its ECO Synthesis™ platform, offering an alternative method for RNA-based therapeutics production. This platform demonstrated coupling efficiency greater than 98% and minimized impurities ...